Daily Endocrinology Research Analysis
Across endocrinology, three studies stand out: a phase 3 RCT in China shows tirzepatide added to basal insulin significantly improves glycemic control; a mechanistic study reveals ATF6α and glucose co-govern β-cell proliferation via E2F1 through CDK4/6–Rb; and a 37-year prospective cohort links polycystic ovarian morphology in PCOS to a higher long-term risk of type 2 diabetes.
Summary
Across endocrinology, three studies stand out: a phase 3 RCT in China shows tirzepatide added to basal insulin significantly improves glycemic control; a mechanistic study reveals ATF6α and glucose co-govern β-cell proliferation via E2F1 through CDK4/6–Rb; and a 37-year prospective cohort links polycystic ovarian morphology in PCOS to a higher long-term risk of type 2 diabetes.
Research Themes
- Incretin-based therapy optimization with basal insulin in T2D
- Mechanistic control of pancreatic β-cell proliferation (ATF6α–E2F1–CDK4/6–Rb)
- PCOS phenotyping and long-term metabolic risk (type 2 diabetes)
Selected Articles
1. Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
In a 40-week, double-blind phase 3 RCT across 26 Chinese hospitals (n=257 randomized), once-weekly tirzepatide (5/10/15 mg) added to basal insulin produced greater reductions in glycemic measures than placebo and was generally well tolerated. These results support tirzepatide as an effective add-on to basal insulin for adults with type 2 diabetes in China.
Impact: High-quality randomized evidence in a large healthcare system demonstrates the efficacy and tolerability of tirzepatide when combined with basal insulin, informing clinical practice where insulin intensification is common.
Clinical Implications: For adults with T2D on basal insulin who need intensification, adding tirzepatide can improve glycemic control with acceptable tolerability. These data support incorporating tirzepatide as an add-on option in Chinese practice and may generalize to similar populations.
Key Findings
- 40-week double-blind, multicentre, randomized, placebo-controlled phase 3 trial in China (n=257 randomized).
- Tirzepatide added to basal insulin achieved greater reductions in glycemic measures (e.g., HbA1c) than placebo.
- Treatment was generally well tolerated across 5/10/15 mg doses.
Methodological Strengths
- Randomized, double-blind, placebo-controlled, multicentre phase 3 design
- Prespecified dosing and standardized 40-week follow-up
Limitations
- Numerical effect sizes for outcomes are truncated in the abstract and long-term outcomes beyond 40 weeks are unknown
- Single-country study; generalizability to non-Chinese settings needs confirmation
Future Directions: Head-to-head comparisons versus other incretin-based regimens and longer-term cardiovascular and renal outcomes in diverse populations are warranted.
BACKGROUND: Data on tirzepatide added to basal insulin in patients with type 2 diabetes in China are scarce. We aimed to evaluate the efficacy and safety of tirzepatide added to basal insulin in this population. METHODS: SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China. Participants aged 18 years or older with uncontrolled type 2 diabetes receiving once-daily insulin glargine alone or in combination with metformin with or without an SGLT2 inhibitor were randomly assigned (1:1:1:1) to once-weekly tirzepatide 5 mg, 10 mg, or 15 mg, or placebo by subcutaneous injection for 40 weeks, stratified by HbA FINDINGS: Between Feb 5, 2023, and July 1, 2024, 331 patients were screened, of whom 257 were randomly assigned to and received tirzepatide 5 mg (n=65), 10 mg (n=65), or 15 mg (n=63), or placebo (n=64). One patient in the tirzepatide 5 mg group and one in the placebo group were inadvertently enrolled and excluded from efficacy analyses. The mean age of 255 patients in the efficacy analysis set was 56·7 years (SD 10·5). 98 (38%) patients were female, and 157 (62%) patients were male. Patients receiving tirzepatide had greater reductions in HbA INTERPRETATION: Tirzepatide added to basal insulin improved glycaemic control and was generally well tolerated, providing evidence to support its potential therapeutic use in patients with type 2 diabetes in China. FUNDING: Eli Lilly and Company. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
2. Dual-Input Regulation of β-Cell Proliferation by ATF6α and Glucose via E2F1.
ATF6α elevates E2F1 abundance but requires high glucose to activate E2F1 via CDK4/6-dependent Rb phosphorylation, providing a dual-input mechanism for β-cell proliferation. In human β-cells, ATF6α increased E2F1 and, with CDK6, augmented proliferation, identifying a therapeutically targetable axis.
Impact: This work uncovers a previously unrecognized coupling between ER stress signaling (ATF6α) and glucose/CDK4/6–Rb control of E2F1 activity, advancing mechanistic understanding of β-cell proliferation and informing regenerative strategies in diabetes.
Clinical Implications: Although preclinical, the ATF6α–E2F1–CDK4/6–Rb axis suggests combinatorial strategies (e.g., ER stress pathway modulation plus CDK4/6 activation) to safely expand human β-cell mass.
Key Findings
- ATF6α increased E2F1 mRNA/protein abundance, but E2F1 activity rose only under high glucose.
- Glucose dependence was mediated by CDK4/6 phosphorylation of Rb, relieving E2F1 repression.
- Thapsigargin increased E2F1 in an ATF6-dependent manner; in human β-cells, ATF6α plus CDK6 enhanced proliferation.
Methodological Strengths
- Mechanistic dissection linking transcriptional control to cell-cycle signaling
- Validation in human β-cells demonstrating translational relevance
Limitations
- Primarily in vitro mechanistic work; no in vivo functional validation of long-term β-cell mass expansion
- Safety and specificity of pathway modulation were not assessed
Future Directions: In vivo validation of ATF6α–E2F1–CDK4/6–Rb modulation for durable β-cell expansion and safety profiling, and exploration of small-molecule modulators.
Endoplasmic reticulum stress response mediator activating transcription factor 6 (ATF6α) increases pancreatic β-cell proliferation in a glucose-dependent manner, but the mechanism remains unknown. ATF6α activation upregulated mRNA and protein expression of E2F1, a key G1/S phase transition regulator; however, E2F1 activity only increased in high glucose. Glucose dependence of E2F1 activity was mediated by cyclin-dependent kinase 4/6 phosphorylation of retinoblastoma (Rb) protein, derepressing E2F1 in high glucose. Generalized endoplasmic reticulum stressor thapsigargin increased E2F1 abundance in an ATF6-dependent manner. ATF6α increased E2F1 expression in human β-cells and increased human β-cell proliferation when cyclin-dependent kinase 6 (CDK6) was coexpressed.
3. Polycystic Ovarian Morphology and Chronic Morbidity and Mortality in PCOS.
In a single-center prospective cohort of 340 women with PCOS followed up to 37 years, those with polycystic ovarian morphology had a higher incidence of non–insulin-dependent diabetes (23.8% vs 9.3%) and evidence of early metabolic derangements, without clear differences in overall mortality or other chronic morbidities.
Impact: Links a readily assessed sonographic phenotype (PCOM) to long-term type 2 diabetes risk, supporting risk stratification and earlier metabolic intervention in a high-prevalence endocrine disorder.
Clinical Implications: Women with PCOS and PCOM may merit intensified metabolic screening and preventive strategies for type 2 diabetes across the lifespan.
Key Findings
- Prospective cohort of 340 women with PCOS; follow-up up to 37 years.
- PCOM associated with higher incidence of non–insulin-dependent diabetes (23.8% vs 9.3%) and early metabolic abnormalities.
- No clear differences in overall mortality or other chronic morbidities between PCOM and non-PCOM.
Methodological Strengths
- Very long follow-up with prospectively collected baseline phenotyping
- Multivariable adjustment for key metabolic confounders
Limitations
- Single-center cohort with potential selection bias and differential follow-up duration between groups
- Observational design precludes causal inference
Future Directions: External validation in multiethnic cohorts and evaluation of targeted prevention in PCOM-positive PCOS.
IMPORTANCE: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder associated with insulin resistance and cardiovascular risk. The long-term association of ovarian morphology subtypes with long-term morbidity and mortality remains unclear. OBJECTIVE: To determine whether long-term morbidity and mortality differ among women with PCOS with or without polycystic ovarian morphology (PCOM). DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted from 1987 to 2005 with follow-up until 2024 (37 years) at a single academic referral center where women with PCOS consented for long-term health monitoring. Of 1089 initially enrolled women, 340 women with PCOS and sonographic data at baseline were included. Data were analyzed from January to April 2024. EXPOSURE: Ovarian morphology was defined by the presence (PCOM) or absence (non-PCOM) of 12 or more peripherally distributed 2- to 9-mm follicles. MAIN OUTCOMES AND MEASURES: All-cause mortality and chronic morbidity, including diabetes and cardiovascular, neurologic, thyroid, respiratory, gastrointestinal, kidney, autoimmune, psychiatric, and cancer conditions were assessed. Demographics, hormone levels, and cardiovascular risk factors were collected at enrollment. Outcomes were assessed at follow-up in older age, with data analyzed using χ2 tests, t tests, and multivariate logistic regression adjusted for confounders (baseline age, body mass index, fasting insulin, lipids, and follow-up duration). RESULTS: Among 340 women with PCOS, 189 women had PCOM (mean [SD] age at enrollment, 28.03 [5.98] years) and 151 women did not (mean [SD] age at enrollment, 32.57 [9.21] years). Women with PCOM were younger at enrollment (P < .001), with higher mean (SD) body mass index (27.20 [5.74] vs 25.31 [6.31]; P = .004), cholesterol ratios (70.64 [51.76] vs 48.36 [51.84]; P < .001), and levels of luteinizing hormone (7.28 [8.60] mIU/mL vs 3.47 [4.39] mIU/mL; P < .001), androgens (eg, total testosterone: 90.78 [37.18] ng/dL vs 52.74 [76.66] ng/dL; P < .001), fasting insulin (12.84 [9.83] μIU/mL vs 8.85 [6.33] μIU/mL; P < .001), total cholesterol (167.57 [63.32] mg/dL vs 147.1 [82.24] mg/dL; P = .01), and triglycerides (97.35 [72.57] mg/dL vs 72.57 [61.06] mg/dL; P < .001). Mean (SD) follow-up duration was shorter in women with PCOM (33.7 [2.3] years vs 35.1 [4.9] years; P < .001). Mortality rates were similar, although mean (SD) age at death was younger in women with PCOM (54.3 [11.5] years vs 70.8 [13.6] years; P = .08). Non-insulin-dependent diabetes was significantly more common in women with PCOM (45 women [23.8%] vs 14 women [9.3%]; P < .001). Hypertension was not statistically significantly different in women with PCOM. Multivariate analysis confirmed the association of PCOM with non-insulin-dependent diabetes (aOR, 2.92; 95% CI, 1.06-2.82; P = .02). No other significant differences in chronic diseases were observed. CONCLUSIONS AND RELEVANCE: In this study, the PCOM pattern was associated with early metabolic abnormalities and increased risk of type 2 diabetes but not with increased mortality or other chronic diseases.